GHRP-6 is a small synthetic peptide that makes the body release a pulse of its own growth hormone — and, famously, makes you hungry while doing it. Its name spells out what it is: Growth-Hormone-Releasing Peptide, number 6. It is built from just six amino acids (the building blocks of proteins), and it works by copying the body's hunger hormone, ghrelin.
In plain terms: a short "release growth hormone now" signal that comes with a strong appetite kick.
What it is
GHRP-6 is a hexapeptide — a chain of six amino acids (its sequence is His-D-Trp-Ala-Trp-D-Phe-Lys). It belongs to the growth-hormone secretagogue family: compounds that make the pituitary gland release growth hormone rather than supplying it directly.
It was one of the original peptides in this class, studied by Cyril Bowers and colleagues years before anyone knew what it was imitating. That answer arrived in 1999, when researchers discovered ghrelin — the natural stomach hormone that GHRP-6 had been mimicking all along2.
How it works — and why hunger comes with it
GHRP-6 activates the GHS-R1a receptor (the growth-hormone-secretagogue receptor), the same lock ghrelin uses2. Switching it on does two things at once:
- In the pituitary, it triggers a burst of growth-hormone release1.
- In the hypothalamus (the brain's appetite-control hub), it lights up the same circuits that make you feel hungry3.
That second effect is the signature of GHRP-6. In a rat study, injecting GHRP-6 into the brain switched on appetite centres — the arcuate and paraventricular nuclei and the lateral hypothalamus — and increased food intake3. So the pronounced hunger people describe is not a random side effect; it is the ghrelin mechanism doing exactly what ghrelin does.
In plain terms: GHRP-6 pulls the ghrelin lever, and that one lever raises both growth hormone and hunger. If you want the growth-hormone pulse *without* the hunger, ipamorelin is the cleaner cousin.
A second, separate lever
GHRP-6 works through a different receptor from the GHRH analogs — sermorelin, CJC-1295, and tesamorelin — which copy growth-hormone-releasing hormone (GHRH). Because the two levers are independent, they can add together: in human studies, GHRP given alongside GHRH produced a bigger growth-hormone response than either alone1. This synergy is why the two families are so often discussed as a pair.
Pharmacokinetics — a quick pulse
GHRP-6 is short-acting. Injected, it produces a growth-hormone pulse within minutes and is then cleared from the blood within roughly an hour — its plasma half-life is on the order of tens of minutes, not hours or days1. That short window is the opposite of the once-daily oral MK-677, which keeps IGF-1 elevated around the clock.
GHRP-6 at a glance
| Property | GHRP-6 |
|---|---|
| Type | Synthetic hexapeptide (6 amino acids) |
| Route studied | Injection (peptide; not oral-stable) |
| Target | Ghrelin / GHS-R1a receptor |
| Signature trait | Strong appetite stimulation |
| Duration | Short — cleared within ~1 hour |
| Human evidence | GH-provocation pharmacology (1990s onward) |
| Other claims (healing, cardioprotection) | Preclinical (animal/cell) |
| Regulatory status | Research compound; not approved |
What the studies actually found
GHRP-6's evidence splits cleanly into two piles. The human pile is about growth-hormone release. The animal pile is about everything else. Keeping them separate is the honest way to read it:
| Study | Model | Key result | Year |
|---|---|---|---|
| Bowers et al.1 | Human (normal men) | GHRP released growth hormone and acted synergistically with GHRH | 1990 |
| Kojima et al.2 | Discovery (rat/human) | Identified ghrelin as the natural hormone GHRP-6 had been mimicking | 1999 |
| Lawrence et al.3 | Rat (brain injection) | GHRP-6 activated hypothalamic appetite centres and increased feeding | 2002 |
| Berlanga et al.4 | Animal (acute myocardial infarction model) | GHRP-6 reduced oxidant damage and cut infarct mass by ~78% | 2007 |
In plain terms: it genuinely raises growth hormone in people1, and in animals it does eye-catching things — protecting heart tissue after a simulated heart attack4 and driving appetite3. But those striking protective findings are preclinical: rats and cells, not human trials.
The honest limitations
- The human evidence is narrow. It covers growth-hormone provocation, mostly from older pharmacology studies1. The regenerative and cardioprotective story that makes GHRP-6 sound exciting is animal-level and has not been confirmed in controlled human trials4.
- The appetite effect is real and can be unwanted3.
- It is not an approved medicine. It is a research peptide, and this page describes its studied mechanism and effects — not how to use it — and takes no position on sourcing.
Latest research
- The cytoprotection angle is the liveliest thread. Building on the 2007 infarction work, the same research lineage has continued to report that GHRP-6 and related peptides protect tissue from oxidative injury in animal models — including newer work on protecting the heart from chemotherapy (doxorubicin) damage4. Interesting, and still preclinical.
- No modern human efficacy trial has moved GHRP-6 beyond its 1990s growth-hormone-provocation base for any therapeutic use. That gap is the story.
- We update this section as new results report.
The short version
GHRP-6 is a six-amino-acid ghrelin mimetic that triggers a short growth-hormone pulse and a strong hunger signal — the appetite effect being its defining trait. It has real (if old) human data on releasing growth hormone, but its healing and heart-protection findings are preclinical, and it is not an approved medicine. Educational overview only. Compare with the cleaner ipamorelin and the diagnostic-grade GHRP-2.